Drug use during pregnancy
DOI:
https://doi.org/10.24265/horizmed.2018.v18n2.11Keywords:
Pregnancy, Drugs, Teratogens, Risk categoryAbstract
There is plenty of information about drug safety during pregnancy, but there is little scientific evidence on this topic. Due to ethical reasons, very scarce clinical assays have been conducted and published. This situation has resulted in the exaggeration of drug risk during pregnancy, thus limiting its reasonable use for chronic diseases in pregnant women. At the other extreme, it has resulted in the careless prescription of drugs not acknowledging the real risk involved in administering them in the inappropriate dose and moment. This review article describes how physiological changes during pregnancy modify significantly the pharmacokinetics of drugs. The real potential risk of drug-induced teratogenesis and the specific criteria for considering them an etiological factor are evaluated. The U.S. Food and Drug Administration (FDA) pregnancy categories' criteria, limitations, and limited current validity are discussed, as well as its proposal of new regulations on drug labeling, considering clinical evaluations, unnoticed exposure, and risks. The risks associated with the most frequently used drugs for the most common diseases during pregnancy are described. The correct way to tell the patient exposed to suspected teratogens is discussed, in order to avoid affecting risk perception. It should be considered that the administration of the most frequently prescribed drugs is relatively safe during pregnancy. Nevertheless, only those strictly necessary must be prescribed, their consumption must be limited during the first trimester, those proven safety must be preferred, the minimum effective dose during the shortest time possible must be used, the administration of several drugs must be avoided, and side effects and complications must be monitored.
Downloads
References
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Reviewer guidance: evaluating the risks of drug exposure in human pregnancies.
Niebyl J, Weber R, and Briggs G. Drugs and Environmental Agents in Pregnancy and Lactation: Teratology, Epidemiology. En: Gabbe SG, Niebyl JR. Niebyl, Simpson JL,et al, editores. Obstetrics: Normal and Problem Pregnancies.7ma ed. Philadelphia: Elsevier; 2017, p.136-158
Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol. 2005;193(3):771-7.
Lockwood C, Magriples U. Initial prenatal assessment and first trimester prenatal care. 2014, UpToDate, Waltham, MA[online] Disponible en: http://www.uptodate.com/contents/initial-prenatal-assessment-and-first-trimester-prenatal
Pietrantoni M. Intoxicaciones durante el embarazo. In: Gleicher. Tratamiento de las complicaciones clínicas del embarazo. 3ª ed. Buenos Aires. Panamericana. 2000: 343- 360
Cuéllar, Santiago, Núñez Manuel y Raposo, Carlos. Uso de medicamentos en embarazo. En: Administración de medicamentos en circunstancias especiales. Ed. Barcelona. 2000, p.2-44. Disponible en: http://www.sld.cu/galerias/pdf/sitios/genetica/medicamentos_y_embarazo.pdf
Clayton-Smith J, Donnai D. Human malformations. En: Rimoin DL, Connor JM, Pyeritz RE, editores. Emery and Rimoin's Principles and Practice of Medical Genetics. 3ra ed. New York: Churchill Livingstone; 1996, p. 383
Cunningham FG, Leveno KJ, Blom SL, Haulth JC, Gilstrap LC, Wenstrom KD. Obstetricia de Williams. 24th ed. Mexico: McGraw Hill; 2015. p240-255
McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology. 1994;50(1):27-37.
Orueta Sánchez R, López Gil MJ. Manejo de fármacos durante el embarazo. Inf Ter Sist Nac Salud. 2011; 35 (4): 107-113.
FDA/CDER SBIA CHRONICLES. Drugs in Pregnancy and Lactation: Improved Benefit-Risk Information. Disponible en. http://www.fda.gov/downloads/Drugs/Development ApprovalProcess/SmallBusinessAssistance/UCM431132.pdf
Gee RE, Wood SF, Schubert KG. Women's health, pregnancy, and the US Food and Drug Administration. Obstet Gynecol. 2014;123(1):161-5.
Pannone R, Cabrera S, Sosa L. Fármacos en el embarazo y la lactancia. Sitio medico [online] http://www.sitiomedico.org/artnac/2002/06/32.htm
Agirrezabala JR. Medicamentos y embarazo: motivos de consulta frecuentes. INFAC. España. 2005;13(1):1-6. Disponible en: http://www.osakidetza.euskadi.net/
Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol. 2002;186(5):S256-S61.
Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol. 1997;14(03):119-24.
Ruigómez A, Rodriguez LAG, Cattaruzzi C, Troncon MG, Agostinis L, Wallander M-A, et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. . Am J Epidemiol. 1999;150(5):476-81.
Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363(22):2114-23.
www.reprotox.org (Accessed on September 20, 2012).
Lin KJ, Mitchell AA, Yau WP, et al. Safety of macrolides during pregnancy. Am J ObstetGynecol 2013; 208:221.e1.
Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. PaediatrPerinatEpidemiol 2009; 23:18.
Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation? Expert Opin Drug Saf 2016; 15:367
Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer SM, Gideon PS, et al. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol. 2009;23(1):18-28.
Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood–time to rebuild its reputation?. Expert Opin Drug Saf. 2016;15(3):367-82.
Bar-Oz B, Moretti ME, Boskovic R, O’Brien L, Koren G. The safety of quinolones—a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2009;143(2):75-8.
Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343(22):1608-14.
Hernández-Díaz S, Werler M, Walker A, Mitchell A. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol. 2001;153(10):961.
Forna F, McConnell M, Kitabire FN, Homsy J, Mermin J, Weidle PJ. Systematic review of the safety of trimethoprim- sulfamethoxazole for prophylaxis in HIV-infected pregnant women: implications for resource-limited settings. AIDS Rev. 2006; 8(1):24-36.
Yau W-P, Mitchell AA, Lin KJ, Werler MM, Hernandez-Diaz S. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol. 2013;178(2):198-208.
Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009;163(11):978-85.
Nordeng H, Lupattelli A, Romøren M, Koren G. Neonatal outcomes after gestational exposure to nitrofurantoin. Obstetrics & Gynecology. 2013;121(2, PART 1):306-13.
Ho P-l, Yip K-S, Chow K-H, Lo JY, Que T-L, Yuen K-y. Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008 Diagn Microbiol Infect Dis. 2010;66(1):87-93.
Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum β-lactamase–producing Escherichia coli. Arch Intern Med. 2008;168(17):1897-902.
Caro-Patón T, Carvajal A, de Diego IM, Martín-Arias LH, Requejo AA, Pinilla ER. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44(2):179-82.
Koss CA, Baras D, Lane SD, Aubry R, Marcus M, Markowitz LE, et al. Investigation of Metronidazole Use during Pregnancy and Adverse Birth Outcomes. Antimicrob Agents Chemother. 2012; 56(9): 4800–4805.
Brees Mark H, Berkow Robert. Manual Merck; 1999:2028- 2033.
Molins A. Antiepileptic drugs in the elderly, pregnant women, children and in systemic disorders. Rev Neurology. 2000; 30(9): 865-872.
ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001.
Campbell E, Kennedy F, Russell A, Smithson W, Parsons L, Morrison P, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014; 85(9): 1029-34.
Dolovich LR, Addis A, Vaillancourt JR, Power JB, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ. 1998;317(7162):839-43.
Wikner BN, Stiller CO, Bergman U, Asker C, Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmaco epidemiol Drug Saf. 2007;16(11):1203-10.
Liew Z, Ritz B, Rebordosa C, Lee P-C, Olsen J. Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. JAMA Pediatr. 2014;168(4):313-20.
Thompson JM, Waldie KE, Wall CR, Murphy R, Mitchell EA, Group AS. Associations between acetaminophen use during pregnancy and ADHD symptoms measured at ages 7 and 11 years. PloS one. 2014;9(9):e108210.
Kristensen DM, Hass U, Lesné L, Lottrup G, Jacobsen PR, Desdoits-Lethimonier C, et al. Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. Hum Reprod. 2010;26(1):235-44.
Ystrom E, Gustavson K, Brandlistuen RE, Knudsen GP, Magnus P, Susser E, et al. Prenatal exposure to acetaminophen and risk of ADHD. Pediatrics.2017:e20163840.
Feldkamp ML, Meyer RE, Krikov S, Botto LD. Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study. Obstet Gynecol. 2010;115(1):109-15.
Nezvalová-Henriksen K, Spigset O, Nordeng H. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study. Br J Obstet Gynecol. 2013;120(8):948-59.
Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am J Obstet Gynecol. 2012;206(3):228. e1-. e8.
Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol. 1997;14(03):119-24.
Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–392.
Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796.
American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013; 122:1122.
Abalos E, Duley L, Steyn D, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;(2): CD002252.
Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407-17.
Peacock WF, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med. 2012;30(6):981-93.
Molvi SN, Mir S, Rana VS, Jabeen F, Malik AR. Role of antihypertensive therapy in mild to moderate pregnancy- induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet. 2012;285(6):1553-62.
Jasper J, Goel R, Einarson A, Gallo M, Koren G. Effects of framing on teratogenic risk perception in pregnant women. Lancet. 2001;358(9289):1237-8.
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
